Like Wegovy and Trulicity, Ozempic belongs to a class of drugs known as glucagon-like peptide-1 agonists, or GLP-1 receptor agonists
You want to know what is legal, what is evidence-based, what requires a prescription, what can go wrong, and how a careful clinician would approach the subject
CMS furnishes Wegovy, Foundayo and the Zepbound KwikPen (not the single-dose vials or pens) for a flat $50 a month to Part D beneficiaries who meet clinical criteria (BMI 35+, or BMI 30+ with heart failure with preserved ejection fraction, uncontrolled hypertension or CKD stage 3a+, or BMI 27+ with pre-diabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease), for weight-management prescriptions only
Research by Jorgensen et al